News

Insulin glargine 300 units/ml is indicated for the treatment of diabetes mellitus in adults and is a novel formulation of the glargine molecule Lantus (insulin glargine 100 units/mL)

The company noted that in a Phase I trial, low-dose veltuzumab, as a single agent, produced an objective response rate of 55% in 38 response-assessable patients with relapsed

The EC’s decision includes Pfizer’s commitment to divest certain sterile injectable drugs and its infliximab biosimilar drug, which is currently under development. Pfizer chairman and chief executive officer

ALX-0061 targets the interleukin 6 pathway via its IL-6 receptor (IL-6R) and is being developed to treat rheumatoid arthritis (RA) and SLE. The trial is designed to identify

A4 is a new clinical trial evaluating solanezumab in the preclinical stage of Alzheimer’s disease in older individuals who have evidence of amyloid in their brains on a

Par’s ethacrynate sodium is the generic version of Valeant Pharmaceuticals North America division Aton Pharma’s Sodium Edecrin, which is indicated for the treatment of edema. According to the

Today the PBM, CVS Caremark published their 2016 Standard Formulary List of Excluded Drugs for their commercial clients. Effective from January 1, 2016 Zubsolv has been removed from

This latest update to the IBgard market authorization allows for the following additional claims on the product label: – helps improve/relieve symptoms of IBS within 24 hours,– helps

The proposal made by Shire was to combine the companies in an all-stock transaction pursuant to which Baxalta shareholders would receive, for each Baxalta share, 0.1687 Shire ADRs.